iNKT Cell Modulators Avoiding Anergy via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iNKT cell activators, such as α-GalCer, induce mixed immune responses and can lead to long-term anergy in iNKT cells, limiting their therapeutic potential due to over-stimulation and potential IL-4 preferential production, which is detrimental for long-term therapies.
Innovation Solution
Development of novel compounds with specific structures that activate iNKT cells by inducing cytokine secretion and upregulating cell surface markers, including IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-15, TNF-α, TNF-β, and IFN-γ, and markers like CD69, CD25, and CD40L, without causing anergy, for use in treating various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α-GalCer is used to activate iNKT cells, then immune response is enhanced, but long-term anergy and unresponsiveness develop
Solution Approach 1:
The patent modifies the chemical structure of α-GalCer by changing parameters such as the glycosidic bond configuration (α to β), sugar moieties, and lipid tail composition to create analogues that activate iNKT cells without inducing anergy. These parameter changes in the ligand structure result in differential TCR signaling that maintains cell responsiveness.
Solution Approach 2:
The invention introduces specific local modifications to the α-GalCer molecule, such as altering individual sugar residues (e.g., replacing galactose with glucose or mannose), modifying the lipid tail saturation, or changing the linkage position. These localized structural changes create compounds with optimized activation profiles that avoid anergy while maintaining potency.
2Power
If iNKT cells are over-stimulated, then cytokine secretion increases, but anergic state and IL-4 preferential production occur
Solution Approach 1:
By systematically varying parameters of the glycolipid structure including the type of sugar (galactose, glucose, mannose, fucose), the configuration of glycosidic bonds (α or β), the length and saturation of lipid tails, and the position of linkage, the patent identifies compounds that elicit balanced cytokine profiles with sustained IFN-γ production and reduced IL-4 bias, avoiding anergy.
Solution Approach 2:
The patent creates structural analogues of α-GalCer that copy the essential features required for CD1d binding and TCR recognition while modifying specific regions to alter signaling outcomes. These copied structures with modified features produce the desired therapeutic effect without the harmful anergic response.
3Adaptability or versatility
If α-GalCer-mediated activation is used, then both Th1 and Th2 cytokines are secreted, but mixed immune response limits therapeutic utility
Solution Approach 1:
The patent utilizes parameter changes in the glycolipid structure to shift the cytokine profile toward Th1 dominance. Specific modifications such as using β-linked sugars, altering lipid chain length, or introducing hydroxyl groups at particular positions result in enhanced IFN-γ and IL-2 production with suppressed IL-4, providing more consistent and predictable therapeutic responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively stimulate iNKT cells, promoting immune responses and potentially offering therapeutic benefits in cancer treatment by avoiding the anergic state and maintaining responsiveness, thus enhancing the efficacy of iNKT cell-based therapies.
Implementation Method 1
The compounds effectively stimulate iNKT cells, promoting immune responses... inducing cytokine secretion... including IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-15, TNF-α, TNF-β, and IFN-γ
Data Source
AI summary
Disclosed herein are α-galactosylceramide (α-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.